Objective-To verify the phenotype to genotype correlations of mitochondrial DNA (mtDNA) related disorders in an atypical maternally inherited encephalomyopathy.
genotype correlations of mitochondrial DNA (mtDNA) related disorders in an atypical maternally inherited encephalomyopathy. Methods-Neuroradiological, morphological, biochemical, and molecular genetic analyses were performed on the affected members of a pedigree harbouring the heteroplasmic A to G transition at nucleotide 3243 of the mitochondrial tRNAI-u(UR), which is usually associated with the syndrome of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS). Results-The proband was affected by a fullblown syndrome of myoclonic epilepsy with ragged red fibres (MERRF), severe brain atrophy, and basal ganglia calcifications, without the MRI T2 hyperintense focal lesions which are pathognomonic of MELAS. Oligosymptomatic relatives were variably affected by lipomas, goitre, brain atrophy, and basal ganglia calcifications. Muscle biopsies in the proband and his mother showed a MELAS-like pattern with cytochrome c oxidase hyperreactive ragged red fibres and strongly succinate dehydrogenase reactive vessels. Quantification of the A3243G mutation disclosed 78% and 70% of mutated mtDNA in the muscle of the severely affected proband and of his oligosymptomatic mother respectively. Nucleotide sequencing of the mitochondrial tRNAIeu(UUR) and tRNALYs in the proband's muscle failed to show any additional nucleotide change which could account for the clinical oddity of this pedigree by modulating the expression of the primary pathogenic mutation. Conclusion-So far, MERRF has been associated with mutations of the mitochondrial tRNALYS, and MELAS with mutations of the mitochondrial tRNALeu(UuR). Now MERRF may also be considered among the clinical syndromes associated with the A to G transition at nt 3243 of the tRNALeu(uuR). ( We discuss here the clinical, neuroradiological, morphological, biochemical, and molecular genetic findings in the affected members of a clinically atypical pedigree harbouring the heteroplasmic A3243G "MELAS" mutation.
Patients and methods

PEDIGREE ANALYSIS
Family member III-1 proband The proband, an 18 year old man, was the firstborn of non-consanguineous parents ( fig  1) . Since the age of 5 years, he had had 3150-3369 for the tRNAL' LUU3R) and nucleotides 8184-8478 for the tRNA"-S, using the "Sequenase PCR product sequencing kit" (Amersham).
Results
MORPHOLOGICAL FINDINGS IN SKELETAL MUSCLE BIOPSIES
The proband's first muscle biopsy (deltoid) showed 8%-10% of ragged red fibres. In the second biopsy (vastus lateralis), ragged red fibres were reduced to 1%-2%, but in many fibres the succinate dehydrogenase staining was stronger than that of normal fibres. The oligosymptomatic mother's muscle biopsy showed 8%-10% of ragged red fibres. Type I fibres were preferentially involved in mitochondrial proliferation. Some ragged red fibres were completely deficient in cytochrome c oxidase, but most showed cytochrome c oxidase hyperreactivity, which was more evident in the periphery of the fibres (fig 3 A,B) . Blood vessels stained darkly with succinate dehydrogenase ( fig 3C) , and were hyperreactive to cytochrome c oxidase. Ultrastructural examination showed intermyofibrillar and subsarcolemmal aggregates of abnormal mitochondria containing paracrystalline inclusions ( fig 3D) . An increased number of mitochondria were also present in the pericytes of capillaries, endothelial cells, and smooth muscle cells of the small arteries. Unlike the clinical phenotype, the morphological abnormalities in muscle followed the pattern seen with the A3243G mutation, which is characterised by ragged red fibres hyperreactive to cytochrome c oxidase and vessels strongly reactive to succinate dehydrogenase.2'
Quantification of the A3243G mutation showed 78% of mutated muscle mtDNA in the proband and 70% in the oligosymptomatic mother. Percentages of mutated mtDNA in blood were 30%, 20%, and 5% in the proband, mother, and grandmother respectively. Recent surveys showed that the percentages of the A3243G mutation did not correlate with the expression of specific clinical syndromes, although, in the MELAS subgroup, the percentage of mutated mtDNA correlated positively with the age of onset of disease.9 1" To explain these imperfect correlations, additional genetic factors involving the mtDNA or the nuclear genome have been hypothesised to modulate the expression of the primary pathogenic mutations of mtDNA.9 Nucleotide sequence analysis of the proband's muscle mtDNA did not show any additional nucleotide change of the tRNAL-\s and tRNAI'u(UUR), which represent two genetic hot spots in maternally inherited syndromes.2' We also excluded the T9957C mutation at the gene for subunit III of cytochrome c oxidase which has been recently reported in MELAS. 22 In conclusion, the presented pedigree challenges the known correlations between the clinical phenotype and the genotype of the mtDNA related disorders, and it indicates that a pure MERRF syndrome must be actually considered as a possible phenotype of the A3243G mutation at the tRNAl-u(UUR). Further molecular genetic studies are needed to disclose other alterations of the mtDNA which could account for the clinical oddity of the described pedigree.
